ArticleAging2014
Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells.
Article in Aging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Common miRNAs, Genes, and Regulatory Pathways in Alzheimer's Disease and Type 2 Diabetes Mellitus: An Integrative Analysis of Systematic Reviews, Bioinformatics and Data Mining.Journal of neurochemistry · 2025Pooled it
- Impacts of systemic milieu on cerebrovascular and brain aging: insights from heterochronic parabiosis, blood exchange, and plasma transfer experiments.GeroScience · 2025Review
- Emerging Biomarkers and Nanobiosensing Strategies in Diabetes.Biosensors · 2025Review
- Integrative Multiparametric Analysis of Circulating Cell-Free Nucleic Acids of Plasma in Healthy Individuals During Aging.Aging cell · 2025Article
- Connecting the Dots: How MicroRNAs Link Asthma and Atherosclerosis.International journal of molecular sciences · 2025Review
- Article
- The serum small non-coding RNA (SncRNA) landscape as a molecular biomarker of age associated muscle dysregulation and insulin resistance in older adults.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review.Frontiers in molecular neuroscience · 2024Review
- Increased small extracellular vesicle levels and decreased miR-126 levels associated with atrial fibrillation and coexisting diabetes mellitus.Clinical cardiology · 2023Article
- Novel insights regarding the role of noncoding RNAs in diabetes.World journal of diabetes · 2023Review
- Article
- Circulating cell-free nucleic acids of plasma in human aging, healthy aging and longevity: current state of knowledge.Frontiers in genetics · 2023Review
- Article
- Relationship of miRNA‑126 and miRNA‑122 expression with type 2 diabetes mellitus and related glucose metabolism parameters: A systematic review and meta‑analysis.Experimental and therapeutic medicine · 2022Article
- Progeria and Aging-Omics Based Comparative Analysis.Biomedicines · 2022Article
- Metabolic imprinting induced by a high-sugar diet: effects on microRNA expression and insulin resistance in young rats.Molecular biology reports · 2022Article
- Stem Cell-derived Exosomal MicroRNA as Therapy for Vascular Age-related Diseases.Aging and disease · 2022Review
- Article
- Review
- Obesity and Severe COVID-19 in the Young: Is Downregulation of miR-126 a Piece of the SARS-COV2 Pathogenicity Puzzle?Archives of medical research · 2022Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating miR-126-3p levels were determined in 136 healthy subjects (CTRs) aged 20-90 years and 193 patients with type-2 diabetes mellitus (T2DMs) aged 40-80 years, to explore the combined effect of age and glycemic state on miR-126-3p expression. Moreover, intra/extracellular miR-126-3p levels were measured in human endothelial cells (HUVECs) undergoing senescence under normo/hyper-glycemic conditions. Plasma miR-126-3p was significantly higher in the oldest compared with the youngest CTRs ( <45 vs. >75 years; relative expression: 0.27±0.29 vs. 0.48±0.39, p=0.047). Age-based comparison between CTRs and T2DM demonstrated significantly different miR-126-3p levels only in the oldest (0.48±0.39 vs. 0.22±0.23, p<0.005). After multiple adjustments, miR-126-3p levels were seen to be lower in patients with poor glycemic control, compared with age-matched CTRs. The age-related increase in plasma miR-126-3p found in CTRs was paralleled by a 5/6-fold increase in intra/extracellular miR-126-3p in in vitro-cultured HUVECs undergoing senescence. Notably, significant down- regulation of SPRED-1 protein, a validated miR-126-3p target, was found in senescent HUVECs. Moreover, miR-126-3p expression was down-regulated in intermediate-age HUVECs grown in high-glucose medium until senescence. Aging/senescence-associated miR-126-3p up-regulation is likely a senescence-associated compensatory mechanism that is blunted when endothelial cells are exposed to high glucose levels, a phenomenon that probably occurs in vivo in T2DM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.